Steven joined DeepCure in 2021 and serves as our Associate Director of Medicinal Chemistry. He has over eight years of drug discovery experience, emphasizing medicinal chemistry and chemical biology. Before joining DeepCure, Steven was a Group Leader at the Broad Institute of MIT and Harvard. He led a group of medicinal chemists who focused on developing novel therapeutic strategies for use in oncology and cardiovascular disease areas. He was essential in advancing several preclinical programs and was a key contributor and co-inventor of inhibitors targeting DHODH (BAY 2402234) and MCL1 (ANJ810). Steven received his Ph.D. in Organic Chemistry from the University of Oxford and was a postdoctoral research associate at Yale University. He also holds a Master of Chemistry from the University of Sheffield.